This Article Full Text Full Text (PDF) All Versions of this Article: 19/6/1593    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reifel-Miller, A. Articles by Brozinick, J. T. Search for Related Content PubMed PubMed Citation Articles by Reifel-Miller, A. Articles by Brozinick, J. T.

A Peroxisome Proliferator-Activated Receptor / Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia

Endocrinology Division (A.R.-M., K.O., E.H., R.R.-P., K.W., J.T.B.), Lead Optimization Biology (R.B., C.R.-M., R.Z.), Cardiovascular Research (W.R.B., C.B., D.S.), and Medicinal and Developmental Chemistry (J.-A.M., G.R., R.R., I.R., T.Z., A.W.), Lilly Research Laboratories, Indianapolis, Indiana 46285; and Ligand Pharmaceuticals (S.D., K.K., D.R.), San Diego, California 92121

Address all correspondence and requests for reprints to: Anne Reifel-Miller, Ph.D., Building 98/C/2331, Endocrinology Division, Lilly Research Laboratories, Indianapolis, Indiana 46285. E-mail: a.r.miller{at}lilly.com.

LSN862 is a novel peroxisome proliferator-activated receptor (PPAR)/ dual agonist with a unique in vitro profile that shows improvements on glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia. Data from in vitro binding, cotransfection, and cofactor recruitment assays characterize LSN862 as a high-affinity PPAR partial agonist with relatively less but significant PPAR agonist activity. Using these same assays, rosiglitazone was characterized as a high-affinity PPAR full agonist with no PPAR activity. When administered to Zucker diabetic fatty rats, LSN862 displayed significant glucose and triglyceride lowering and a significantly greater increase in adiponectin levels compared with rosiglitazone. Expression of genes involved in metabolic pathways in the liver and in two fat depots from compound-treated Zucker diabetic fatty rats was evaluated. Only LSN862 significantly elevated mRNA levels of pyruvate dehydrogenase kinase isozyme 4 and bifunctional enzyme in the liver and lipoprotein lipase in both fat depots. In contrast, both LSN862 and rosiglitazone decreased phosphoenol pyruvate carboxykinase in the liver and increased malic enzyme mRNA levels in the fat. In addition, LSN862 was examined in a second rodent model of type 2 diabetes, db/db mice. In this study, LSN862 demonstrated statistically better antidiabetic efficacy compared with rosiglitazone with an equivalent side effect profile. LSN862, rosiglitazone, and fenofibrate were each evaluated in the humanized apoA1 transgenic mouse. At the highest dose administered, LSN862 and fenofibrate reduced very low-density lipoprotein cholesterol, whereas, rosiglitazone increased very low-density lipoprotein cholesterol. LSN862, fenofibrate, and rosiglitazone produced maximal increases in high-density lipoprotein cholesterol of 65, 54, and 30%, respectively. These findings show that PPAR full agonist activity is not necessary to achieve potent and efficacious insulin-sensitizing benefits and demonstrate the therapeutic advantages of a PPAR/ dual agonist.

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARα  |  PPARδ  |  PPARγ

Coregulators:   TRAP220  |  PGC-1  |  CBP  |  ASC-2

Ligands:   Rosiglitazone

This article has been cited by other articles:

				D. R. Cha, X. Zhang, Y. Zhang, J. Wu, D. Su, J. Y. Han, X. Fang, B. Yu, M. D. Breyer, and Y. Guan Peroxisome Proliferator Activated Receptor {alpha}/{gamma} Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice Diabetes, August 1, 2007; 56(8): 2036 - 2045. [Abstract] [Full Text] [PDF]

				Y. Liu, M. D. Michael, S. Kash, W. R. Bensch, B. P. Monia, S. F. Murray, K. A. Otto, S. K. Syed, S. Bhanot, K. W. Sloop, et al. Deficiency of Adiponectin Receptor 2 Reduces Diet-Induced Insulin Resistance but Promotes Type 2 Diabetes Endocrinology, February 1, 2007; 148(2): 683 - 692. [Abstract] [Full Text] [PDF]

				A. Tsuchida, T. Yamauchi, S. Takekawa, Y. Hada, Y. Ito, T. Maki, and T. Kadowaki Peroxisome Proliferator-Activated Receptor (PPAR){alpha} Activation Increases Adiponectin Receptors and Reduces Obesity-Related Inflammation in Adipose Tissue: Comparison of Activation of PPAR{alpha}, PPAR{gamma}, and Their Combination Diabetes, December 1, 2005; 54(12): 3358 - 3370. [Abstract] [Full Text] [PDF]